ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2019
Burden Of Treatment Among Patients Undergoing Intravitreal Injections For Diabetic Macular Oedema In Australia.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Use of Aflibercept 8 mg for the Treatment of Diabetic Macular Edema in Italy: A Cost-Minimisation Analysis Based on an Indirect Treatment Comparison.Advances in therapy · 2026Pooled it
- Clinical practice guidelines for the treatment and management of diabetic macular oedema: a systematic review.Eye (London, England) · 2025Pooled it
- Topical bromfenac in VEGF-driven maculopathies: topical review and meta-analysis.BMC ophthalmology · 2024Pooled it
- Oral lamivudine in diabetic macular edema: A randomized, double-blind, placebo-controlled clinical trial.Med (New York, N.Y.) · 2025Trial
- Faricimab in Treatment-Naïve nAMD: Regional UK Real-World Experience.Advances in therapy · 2026Article
- Characterizing and assessing vision-related quality of life among patients discontinued treatment for neovascular age-related macular degeneration.Acta ophthalmologica · 2026Article
- Intravitreal faricimab in patients with refractory diabetic macular edema: 6-month fluid analysis using artificial intelligence.BMC ophthalmology · 2026Observational
- Anatomical and Systemic Predictors of Early Response to Subthreshold Micropulse Laser in Diabetic Macular Edema: A Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Quantifying the direct costs of diabetic retinopathy in a mixed healthcare system: a hospital-based study from governmental and patient perspectives.Cost effectiveness and resource allocation : C/E · 2026Article
- Quercetin attenuates high glucose-induced VEGFA expression in ARPE-19 cells by inhibiting ROS generation, p38 MAPK phosphorylation, and NF-κB activation.Scientific reports · 2026Article
- Nanotechnology-Based Treatment for Ophthalmic Diseases.International journal of nanomedicine · 2026Review
- Article
- Twelve-Month Outcomes of Faricimab for Patients with Sub-Optimally Responsive Diabetic Macular Oedema: A Retrospective Single-Centre Study.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Comparative efficacy of intravitreal aflibercept biosimilar QL1207 versus reference aflibercept in the treatment of diabetic macular edema.Frontiers in medicine · 2025Article
- Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia.Journal of health economics and outcomes research · 2025Article
- Nanomedicine in Ophthalmology: From Bench to Bedside.Journal of clinical medicine · 2024Review
- Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: guidance from a UK panel of retina specialists.Eye (London, England) · 2024Article
- Real-World Outcomes of Faricimab Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema.Clinical ophthalmology (Auckland, N.Z.) · 2024Article
- Exploring the role of retinal fluid as a biomarker for the management of diabetic macular oedema.Eye (London, England) · 2024Review
- Oxidative Stress and Its Regulation in Diabetic Retinopathy.Antioxidants (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThe incidence and prevalence of diabetes mellitus (DM) in Australia is increasing. Thus, it is essential that practitioners appreciate the impending effect that increasing incidence of diabetes has on patients and the wider community. Accordingly, this study examines the humanistic burden of intravitreal injections for the treatment of diabetic macular oedema (DMO) among several health variables.
methodsSurvey data from a representative sample of Australian adults undergoing treatment for DMO were examined. Respondents participated via an online survey recruited by means of a national online consumer panel and the New South Wales and Victorian Diabetes Foundations. The online survey included questions relating to the humanistic burden of disease, such as the emotional and physical impact of intravitreal injection therapy; the practical impacts of injection therapy; and to identify potential improvements to treatment regimens.
resultsSixty-five participants took part in the online survey. Of these, 49% had their most recent injection <1 month prior to completing the survey. The mean age was 52.5 years, with the majority of patients in full-time work. A substantial proportion of participants had several comorbidities, with a significantly high Charlson comorbidity index of 2.7. Participants reported the main burden of DMO care was the direct cost of medical treatment and the time burden demanded upon their carers. Results suggest that the overall burden is significant for those with diabetes and increases as additional complications of diabetes occur.
conclusionThese results suggest that treatment strategies for DMO should consider clinical, humanistic and economic burden and patients should be educated on the roles of complications in disease outcomes. Less frequent treatment regimens could also reduce the economic burden and assist in decreasing the effect on health care resources, relevant to the escalation in the prevalence of diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.